249.4: COVID-19 Outcomes After Widespread Vaccine Availability in Kidney Transplant Recipients

Le résumé fourni par la source

Introduction: In 2020, 16% of deaths among kidney transplant (KT) recipients in the United States were due to COVID-19, and KT recipients remain at high risk for severe complications. The impact of vaccination on COVID-19 outcomes in KT recipients remains incompletely described. Our aim was to review the outcomes of our center’s KT recipients who contracted COVID-19 after the availability of vaccines. Methods: We retrospectively reviewed all KT recipients at Wake Forest Baptist Medical Center (Winston-Salem, North Carolina, USA) performed between 2016 and 2020 with a known laboratory-proven diagnosis of COVID-19 from 03/2021 through 02/2022. Demographic, vaccination, hospitalization and outcome information were reviewed for these patients. Results: 1017 patients underwent kidney transplantation at our center between 2016-2020, including 11 patients who died of COVID-19 complications prior to March 2021. We identified 58 patients (5.7%) with laboratory-proven COVID-19 between March 2021 and February 2022. Of these patients, 33 (56.9%) were men and 25 (43.1%) were women. The average age at COVID-19 diagnosis was 53 years (+/- 16.8). 27 patients (46.4%) were Black, 24 (41.4%) were White, 1 (1.7%) was Native American, and the remaining 7 (10.3%) were Asian, Native American, or other groups. 5 (8.6%) identified as Hispanic/Latino. Compared with the total KT population for the study period, COVID-19 was diagnosed in 33/539 (6.1%) of men, 25/478 (5.2%) of women, 24/518 (4.6%) of White patients, 27/414 (6.5%) of Black patients, 5/50 (10%) of Hispanic/Latino patients, and 7/85 (8.2%) of other groups. Of the patients with COVID-19, 42/58 (72.4%) had received at least one vaccine dose. 8 patients were infected with COVID-19 between 3/1/21 and 6/30/21, 16 during the Delta variant from 7/1/21 to 11/15/21, and 34 during the Omicron variant from 11/16/21 and 3/1/2022. Venous thromboembolism occurred in 7/58 patients (12.1%), acute kidney injury in 26/58 (44.8%), and transplant rejection in 1/58 (1.7%). Overall, 31/58 patients required hospitalization (53.4%), 10/58 required ICU admission (17.2%), and 6/58 died (10.3%). Of these deaths, 5 occurred in the hospital, while 1 occurred at home shortly after hospital discharge. Conclusion: In this single-center analysis, we identified a high risk for severe complications of COVID-19 in KT recipients, even with vaccination. Overall, COVID-19 mortality was lower following vaccine availability in our center compared with the pre-vaccine period. Our present cohort size is almost certainly an underestimate, but there was a marked increase in diagnosed cases during the Omicron wave compared with earlier variants. A majority of identified patients required hospitalization, with a high risk for death. Infection appeared more common in minority groups and in men. Continued precautions will be necessary to protect KT recipients during the ongoing pandemic.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.